Omnicell (OMCL) Downgraded by BidaskClub to “Sell”
BidaskClub cut shares of Omnicell (NASDAQ:OMCL) from a hold rating to a sell rating in a research note released on Friday.
OMCL has been the topic of several other reports. Benchmark boosted their target price on Omnicell from $55.00 to $67.00 and gave the company a buy rating in a research note on Tuesday, September 5th. Cantor Fitzgerald restated a buy rating and issued a $60.00 target price on shares of Omnicell in a research note on Tuesday, December 5th. Oppenheimer restated a buy rating and issued a $55.00 target price on shares of Omnicell in a research note on Thursday, October 19th. Craig Hallum restated a buy rating and issued a $62.00 target price (up from $52.00) on shares of Omnicell in a research note on Monday, October 30th. Finally, Zacks Investment Research lowered Omnicell from a hold rating to a strong sell rating in a research note on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $55.14.
Shares of Omnicell (NASDAQ:OMCL) traded down $0.40 during trading on Friday, reaching $49.55. The company had a trading volume of 115,422 shares, compared to its average volume of 257,434. The company has a market capitalization of $1,894.72, a price-to-earnings ratio of -450.45, a P/E/G ratio of 26.43 and a beta of 0.71. Omnicell has a 1-year low of $31.85 and a 1-year high of $55.40. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.38.
Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.42. The firm had revenue of $186.78 million for the quarter, compared to analyst estimates of $192.45 million. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The business’s revenue was up 5.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.40 earnings per share. research analysts anticipate that Omnicell will post 0.12 EPS for the current fiscal year.
In related news, EVP Dan S. Johnston sold 14,613 shares of the business’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $47.81, for a total transaction of $698,647.53. Following the sale, the executive vice president now directly owns 43,621 shares in the company, valued at approximately $2,085,520.01. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Peter J. Kuipers sold 3,532 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $50.96, for a total value of $179,990.72. Following the sale, the vice president now owns 40,714 shares in the company, valued at $2,074,785.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,090 shares of company stock worth $1,510,221. 3.77% of the stock is currently owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in shares of Omnicell by 2.3% during the 2nd quarter. BlackRock Inc. now owns 4,589,119 shares of the company’s stock valued at $197,790,000 after purchasing an additional 101,776 shares during the period. Vanguard Group Inc. raised its stake in shares of Omnicell by 3.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,928,201 shares of the company’s stock valued at $83,105,000 after purchasing an additional 67,902 shares during the period. Conestoga Capital Advisors LLC raised its stake in shares of Omnicell by 0.7% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,617,706 shares of the company’s stock valued at $82,584,000 after purchasing an additional 11,105 shares during the period. Oak Ridge Investments LLC raised its stake in shares of Omnicell by 0.6% during the 2nd quarter. Oak Ridge Investments LLC now owns 1,537,940 shares of the company’s stock valued at $66,285,000 after purchasing an additional 8,491 shares during the period. Finally, Janus Henderson Group PLC grew its position in Omnicell by 129.6% during the second quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock worth $53,096,000 after buying an additional 695,334 shares in the last quarter. Institutional investors own 99.61% of the company’s stock.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.